Necroptosis has emerged as an important pathway of programmed cell death in embryonic development, tissue homeostasis, immunity and inflammation [1] [2] [3] [4] [5] [6] [7] [8] . RIPK1 is implicated in inflammatory and cell death signalling [9] [10] [11] [12] [13] and its kinase activity is believed to drive RIPK3-mediated necroptosis 14, 15 . Here we show that kinase-independent scaffolding RIPK1 functions regulate homeostasis and prevent inflammation in barrier tissues by inhibiting epithelial cell apoptosis and necroptosis. Intestinal epithelial cell (IEC)-specific RIPK1 knockout caused IEC apoptosis, villus atrophy, loss of goblet and Paneth cells and premature death in mice. This pathology developed independently of the microbiota and of MyD88 signalling but was partly rescued by TNFR1 (also known as TNFRSF1A) deficiency. Epithelial FADD ablation inhibited IEC apoptosis and prevented the premature death of mice with IEC-specific RIPK1 knockout. However, mice lacking both RIPK1 and FADD in IECs displayed RIPK3-dependent IEC necroptosis, Paneth cell loss and focal erosive inflammatory lesions in the colon. Moreover, a RIPK1 kinase inactive knock-in delayed but did not prevent inflammation caused by FADD deficiency in IECs or keratinocytes, showing that RIPK3-dependent necroptosis of FADDdeficient epithelial cells only partly requires RIPK1 kinase activity. Epidermis-specific RIPK1 knockout triggered keratinocyte apoptosis and necroptosis and caused severe skin inflammation that was prevented by RIPK3 but not FADD deficiency. These findings revealed that RIPK1 inhibits RIPK3-mediated necroptosis in keratinocytes in vivo and identified necroptosis as a more potent trigger of inflammation compared with apoptosis. Therefore, RIPK1 is a master regulator of epithelial cell survival, homeostasis and inflammation in the intestine and the skin.
Necroptosis has emerged as an important pathway of programmed cell death in embryonic development, tissue homeostasis, immunity and inflammation [1] [2] [3] [4] [5] [6] [7] [8] . RIPK1 is implicated in inflammatory and cell death signalling [9] [10] [11] [12] [13] and its kinase activity is believed to drive RIPK3-mediated necroptosis 14, 15 . Here we show that kinase-independent scaffolding RIPK1 functions regulate homeostasis and prevent inflammation in barrier tissues by inhibiting epithelial cell apoptosis and necroptosis. Intestinal epithelial cell (IEC)-specific RIPK1 knockout caused IEC apoptosis, villus atrophy, loss of goblet and Paneth cells and premature death in mice. This pathology developed independently of the microbiota and of MyD88 signalling but was partly rescued by TNFR1 (also known as TNFRSF1A) deficiency. Epithelial FADD ablation inhibited IEC apoptosis and prevented the premature death of mice with IEC-specific RIPK1 knockout. However, mice lacking both RIPK1 and FADD in IECs displayed RIPK3-dependent IEC necroptosis, Paneth cell loss and focal erosive inflammatory lesions in the colon. Moreover, a RIPK1 kinase inactive knock-in delayed but did not prevent inflammation caused by FADD deficiency in IECs or keratinocytes, showing that RIPK3-dependent necroptosis of FADDdeficient epithelial cells only partly requires RIPK1 kinase activity. Epidermis-specific RIPK1 knockout triggered keratinocyte apoptosis and necroptosis and caused severe skin inflammation that was prevented by RIPK3 but not FADD deficiency. These findings revealed that RIPK1 inhibits RIPK3-mediated necroptosis in keratinocytes in vivo and identified necroptosis as a more potent trigger of inflammation compared with apoptosis. Therefore, RIPK1 is a master regulator of epithelial cell survival, homeostasis and inflammation in the intestine and the skin.
Mice lacking RIPK1 die perinatally, exhibiting apoptosis in multiple tissues including the intestine 9 (Extended Data Fig. 1a ). We generated mice with IEC-specific knockout of RIPK1 (RIPK1 IEC-KO ) ( Fig. 1a and Extended Data Fig. 1b-d ) and found that they showed reduced body weight and died within the first 4 weeks of life (Fig. 1b, c) . Intestinal sections from 3-week-old RIPK1 IEC-KO mice revealed pronounced villus atrophy and Paneth cell loss in the ileum, as well as reduced numbers of goblet cells and differentiated enterocytes, crypt elongation and IEC hyperproliferation in both the ileum and colon ( Fig. 1d and Extended Data Fig. 1e, f) . RIPK1
IEC-KO intestines contained highly increased numbers of cleaved caspase-3-positive (CC3 1 ) apoptotic IECs, but did not show signs of epithelial erosion, suggesting that the epithelial barrier remained largely intact ( Fig. 1d and Extended Data Fig. 1e, f) . Messenger RNA levels of Tnf, Il1b, Ccl5 and Cxcl1 and leukocyte numbers were moderately increased in the ileum and colon of RIPK1 IEC-KO mice (Fig. 1e , f and Extended Data Fig. 2 ), indicating the presence of a mild inflammatory response. Newborn RIPK1 IEC-KO mice showed only a few apoptotic IECs, while 7-day-old mice showed increased numbers of apoptotic IECs, loss of goblet cells, elongated hyperproliferative crypts and increased immune cell infiltration concomitant with moderately increased expression of tumour necrosis factor (TNF) and interleukin (IL)-1b (Extended Data Fig. 3 ). Tamoxifen-inducible ablation of RIPK1 in IECs of adult mice (RIPK1 tamIEC-KO ) caused rapid weight loss and death of the animals (Extended Data Fig. 4a-d ) due to extensive IEC apoptosis resulting in severe intestinal pathology (Extended Data Fig.  4e-i) . Collectively, these results revealed that epithelial-cell-intrinsic RIPK1 is essential for IEC survival and the maintenance of intestinal tissue structure and homeostasis.
The luminal microbiota regulates intestinal homeostasis and contributes to inflammation both in human inflammatory bowel disease and in mouse models 16, 17 . Antibiotic treatment briefly delayed but did not prevent severe intestinal pathology, weight loss and death of mice with inducible or constitutive IEC-specific RIPK1 knockout (Extended Data Fig. 4c -e, j-l). Moreover, RIPK1
IEC-KO mice raised under germ-free conditions developed similar intestinal pathology, although some of the mice survived up to the age of 5 weeks, indicating that the microbiota contributes to disease severity ( Fig. 1g-j) . In addition, MyD88 deficiency did not prevent intestinal pathology in RIPK1 IEC-KO mice (Fig. 2a , b, d and Extended Data Fig. 5a-c) . Therefore, epithelial cell death and intestinal pathology in RIPK1 IEC-KO mice develop independently of the microbiota and of MyD88-dependent TLR signalling. RIPK1
IEC-KO /Tnfr1
2/2 mice were partially protected from severe wasting, with approximately 50% of the mice surviving to at least 3 months of age, and showed reduced IEC apoptosis and ameliorated intestinal pathology (Fig. 2a-e and Extended Data Fig. 5a-c) . Thus, IEC death and intestinal pathology in RIPK1 IEC-KO mice is induced mainly by TNFR1 signalling but TNFR1-independent pathways also contribute.
Epithelial FADD deficiency inhibited IEC apoptosis and villus atrophy and prevented the severe wasting and premature death of RIPK1 IEC-KO mice ( Fig. 2f-h ), suggesting an important pathogenic role of FADDdependent apoptosis. However, RIPK1
IEC-KO /FADD IEC-KO intestines contained increased numbers of CC3 2 dying IECs and showed Paneth cell loss in the ileum and signs of colitis affecting primarily the distal colon (Fig. 2f, and Il10 in the colon (Fig. 2f-k and Extended Data Figs 5d, e, 6, 7a, b Fig. 7c, d) . Therefore, RIPK1 deficiency or loss of its kinase activity only partly inhibited RIPK3-dependent necroptosis of FADD-deficient IECs, providing genetic evidence that both RIPK1-dependent and RIPK1-independent pathways drive RIPK3-mediated necroptosis and intestinal inflammation in FADD IEC-KO mice. As shown previously 9, 18 , RIPK1 deficiency but not loss of its kinase activity partially inhibited TNF-mediated NF-kB activation in mouse embryonic fibroblasts (MEFs) (Extended Data Fig. 8a ), suggesting that loss of RIPK1 scaffolding function might trigger epithelial cell apoptosis by inhibiting NF-kB. However, NF-kB inhibition in the intestinal epithelium did not phenocopy the intestinal pathology of RIPK1 IEC-KO mice [19] [20] [21] . Moreover, sustained NF-kB activation in RIPK1-deficient epithelial cells by expression of a constitutively active Ikk2 transgene 22, 23 did not prevent IEC death and rather aggravated the intestinal pathology of RIPK1
IEC-KO mice, suggesting that RIPK1 deficiency does not sensitize IECs to apoptosis by inhibiting NF-kB (Extended Data Fig. 8b-d) .
RIPK1-deficient IECs did not show reduced mRNA expression of prosurvival genes, but expressed reduced amounts of cIAP1 (also known as BIRC2) and TRAF2 proteins (Fig. 3a, b) , suggesting that RIPK1 might control their stability. Indeed, consistent with previous reports 24 , 25 , we found that TNF stimulation induced rapid degradation of TRADD, cIAP1, TRAF2 and c-FLIP (also known as CFLAR), but not of TRAF6, in RIPK1-deficient but not in RIPK1(D138N) primary MEFs (Fig. 3c) , suggesting that lack of the RIPK1 scaffolding function triggers degradation of proteins recruited to the TNFR1 signalling complex. We then sought to address whether RIPK1-deficient intestinal epithelial cells show similar responses. However, small intestinal crypts from RIPK1 IEC-KO mice died shortly after isolation and failed to form organoids (data not shown). Nevertheless, tamoxifen-inducible RIPK1 deletion resulted in reduced expression of cIAP1, TRAF2 and c-FLIP proteins and caused rapid organoid death (Fig. 3d-f) , suggesting that loss of pro-survival protein expression contributes to death of RIPK1-deficient IECs. Interestingly, TRAF2-deficient mice develop a similar intestinal phenotype and early lethality that was not prevented by antibiotic treatment and was only partially rescued by TNFR1 deficiency, suggesting that loss of TRAF2 could contribute to the intestinal pathology of RIPK1 IEC-KO mice 26 . SMAC (also known as DIABLO) mimetic-compound-mediated cIAP1/2 degradation induced activation of both non-canonical and canonical NF-kB and the expression of TNF and other cytokines 27, 28 , suggesting that loss of cIAP proteins could trigger the expression of TNF and other cytokines by RIPK1-deficient IECs that could act in an autocrine fashion to induce their death. Indeed, RIPK1-deficient primary IECs showed increased NF-kB activation and expressed elevated levels of TNF, while tamoxifen-inducible deletion of RIPK1 upregulated TNF expression in organoids ( Fig. 3g-j) . Moreover, intestinal crypts from RIPK1
mice did not die rapidly, as did crypts from RIPK1 IEC-KO mice, and although they did not grow as well as control organoids they could be maintained for a short period in culture (Fig. 3k) , consistent with a role of autocrine TNF production in triggering the death of RIPK1-deficient IECs. RIPK1/TNFR1 double-deficient organoids were more sensitive to 1 cells (i) and CC3 1 cells per crypt (j) in intestinal sections of the indicated mice. GF, germ free; SPF, specific pathogen free. Scale bars, 100 mm. *P # 0.05, **P # 0.01, ***P # 0.005; NS, not significant.
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death induced by polyinosinic:polycytidylic acid (poly(I:C)), interferon (IFN)-b and IFN-c (Fig. 3k) , indicating that TIR-domain-containing adapter-inducing interferon-b (TRIF)-and IFN-dependent pathways also contribute to the death of RIPK1-deficient IECs. However, IEC-specific ablation of TRIF did not considerably ameliorate intestinal pathology in RIPK1
IEC-KO mice (Extended Data Fig. 8e-h ), suggesting that TRIFmediated signalling is not a major driver of IEC apoptosis but could contribute in a redundant fashion together with TNFR1 and IFN signalling. Together, these findings suggest that RIPK1 deficiency results in degradation of cIAP proteins and TRAF2, triggering NF-kB-mediated expression of TNF and other cytokines that act in a partly redundant fashion to induce the death of RIPK1-deficient IECs. The mild upregulation of Tnf in the colon of RIPK1 (Fig. 2k) is compatible with this epithelial cell death independent mechanism inducing Tnf expression, which also provides a microbiotaindependent trigger of IEC death in RIPK1 IEC-KO mice. To investigate the function of RIPK1 in the epidermis, we generated mice with keratinocyte-specific RIPK1 deficiency (RIPK1 E-KO mice) (Extended Data Fig. 9a) . RIPK1 E-KO mice progressively developed severe inflammatory skin lesions starting at around 1 week of age, characterized by epidermal thickening, increased keratin 14 (K14; also known as KRT14) and reduced K10 expression and upregulation of K6 in the interfollicular epidermis, as well as infiltration of Gr-1-positive cells and increased inflammatory cytokine and chemokine expression (Fig. 4a-c and Extended Data Fig. 9a, b) . Histological analysis revealed the presence of CC3 1 but also CC3 2 dying keratinocytes, identified by their pyknotic nuclei and eosinophilic cytoplasm in the epidermis of RIPK1 E-KO mice ( Fig. 4d and Extended Data Fig. 9d) . To address the role of FADD-mediated apoptosis, we generated FADD E-KO mice (Fig. 4a, b) . Therefore, lack of RIPK1 or its kinase activity delayed but could not prevent keratinocyte necroptosis and inflammation caused by FADD deficiency. Additional deficiency in RIPK3 fully prevented skin inflammation in RIPK1 Fig. 9d , e, g), showing that RIPK3-mediated necroptosis of RIPK1-deficient keratinocytes causes the inflammatory skin lesions. CRISPR/Cas9-mediated knockout of MLKL also prevented skin inflammation in RIPK1 E-KO mice, further supporting an essential role of RIPK3/MLKL-dependent necroptosis in this model (Extended Data Fig. 10) . Therefore, at least in the context of keratinocyte-specific RIPK1 deficiency, necroptosis of keratinocytes triggers skin inflammation but apoptosis does not, highlighting the different immune regulatory properties of these programmed cell death pathways in a diseaserelevant in vivo experimental setting. Considering that Ripk1 D138N/D138N mice did not develop skin lesions (Fig. 4a) , these results show that RIPK1 acts through a kinase-independent scaffolding function to restrain RIPK3-mediated necroptosis in keratinocytes and prevent skin inflammation. RIPK1
E-KO /Tnfr1 2/2 mice showed largely normal skin until postnatal day (P)28, but developed patchy inflammatory skin lesions by the age of 7-8 weeks (Fig. 4a-d and Extended Data Fig. 9d, e, g ). Therefore, TNFR1 critically contributes but is not the only trigger of keratinocyte necroptosis 
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E-KO mice. Keratinocyte-specific TRIF ablation also mildly ameliorated skin lesion development in RIPK1 E-KO mice (Fig. 4a, b and Extended Data Fig. 9e ). Collectively, these results showed that TNFR1-and TRIF-mediated signalling contribute to RIPK3-dependent keratinocyte necroptosis and skin inflammation in RIPK1 E-KO mice.
cIAP1 was expressed at very low levels at steady state and was undetectable after TNF stimulation in RIPK1-deficient primary keratinocytes (Fig. 4e) , similar to our findings in IECs. Moreover, RIPK1-deficient primary keratinocytes were highly sensitive to TNF-induced death that was inhibited by the caspase inhibitor z-VAD-FMK, demonstrating that in vitro these cells died primarily by apoptosis and were resistant to necroptosis even though they expressed RIPK3 (Fig. 4f, g ). This result 
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is surprising considering that RIPK1 deficiency in vivo triggers skin inflammation by sensitizing keratinocytes to RIPK3-dependent necroptosis, and suggests that mechanisms related to keratinocyte differentiation and the in vivo tissue context could determine the sensitivity of keratinocytes to apoptosis and necroptosis. Collectively, our results revealed a novel kinase-independent scaffolding function of RIPK1 as an inhibitor of epithelial cell apoptosis and necroptosis in vivo that is essential for the maintenance of physiological tissue homeostasis in the intestine and the skin. The mechanisms determining whether RIPK1 deficiency sensitizes epithelial cells to apoptosis or necroptosis remain unclear and do not seem to depend on differential expression of RIPK3 (Fig. 4g) . Our experiments also showed that necroptosis of FADD-deficient IECs and keratinocytes only partly depends on RIPK1 kinase activity, demonstrating that both RIPK1-dependent and -independent pathways drive RIPK3-mediated necroptosis. Therefore, RIPK1 is a central regulator of cell death that has the capacity to either inhibit or induce apoptosis and necroptosis (Fig. 4h) . Considering its key role as a molecular hub integrating and decoding multiple ubiquitination (K63, K48, linear) signals to determine cellular responses to stimuli that are derived (for example, lipopolysaccharide, double-stranded RNA) or induced (for example, TNF, IFNs) by microbes and are capable of triggering both inflammation and cell death, RIPK1 emerges as a key regulator of immunity and homeostasis in barrier tissues.
Note added in proof: An accompanying paper (Takahashi, N. et al., Nature http://dx.doi.org/10.1038/nature13706) reports similar results on the role of RIPK1 in preventing IEC apoptosis, with some differences on the effect of antibiotic treatment and MYD88 deficiency on the intestinal pathology of RIPK1 IEC-KO mice.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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/Ripk1
fl/fl mice a modified version of the first protocol was employed, where Meronem was replaced by 0.5 g l 21 vancomycin (Eberth). As neither the overall physiological response nor tissue pathology differed between the two regimens, mouse groups receiving either antibiotic mixture were analysed together and data from individual experiments were pooled. VillinCreER T2 recombinase activity was induced by three daily intraperitoneal administrations of 1 mg tamoxifen. Littermates not carrying the Villin-Cre, Villin-CreER T2 and K14-Cre transgenes were used as controls in all experiments. Mice of the indicated genotype were assigned at random to groups. Mouse studies were performed in a blinded fashion. Unless otherwise indicated, mice were analysed at 3 weeks of age. Groups included male and female animals. Targeting of the Mlkl gene in zygotes from RIPK1 E-KO mice. Fertilized oocytes obtained from breedings of K14-Cre; Ripk1 fl/wt males with Ripk1 fl/fl females were microinjected with Mlkl short guiding (sg)RNA and Cas9 mRNA. sgRNA and truncated sgRNA were prepared by in vitro transcription of T7-promoter and sgRNA targeting sequence containing PCR products. These sgRNA templates were generated using a long sgRNA forward primer containing the T7 promoter (59-TTAATACGA CTCACTATAGG-39) used for in vitro transcription, 20 bp sgRNA (59-CGTCTAGG AAACCGTGTGCA-39) or 18 bp sgRNA_TRUNC 39 (59-TCTAGGAAACCGTGTG CA-39) targeting sequence and 20 bp homology to the px330 template (59-GTTTTA GAGCTAGAAATAGC-39; Zhang laboratory, Addgene plasmid 42230). The forward primer for MLKL_sgRNA is 59-TTAATACGACTCACTATAGGCGTCTAGGAA ACCGTGTGCAGTTTTAGAGCTAGAAATAGC-39 and the forward primer for MLKL_sgRNA_TRUNC is 59-TTAATACGACTCACTATAGGTCTAGGAAACC GTGTGCAGTTTTAGAGCTAGAAATAGC-39. The long forward primers were used together with sgRNA_rev (59-AAAAAGCACCGACTCGGTGCC-39) to amplify the chimaeric sgRNA template from px330. The resulting 121 bp or 119 bp PCR product (MLKL_sgRNA or MLKL_sgRNA_TRUNC) was used for in vitro transcription using the T7 High Yield in vitro transcription kit (NEB) and sgRNA was purified using RNA isolation columns (Macherey Nagel). Fertilized oocytes were injected at 0.5 days post-coitum (dpc) with 100 ng ml 21 Cas9 mRNA (TriLink) together with 50 ng ml 21 sgRNA and the surviving two-cell-stage embryos were transferred the next day to foster mothers. Progeny was genotyped using the following primers: typing_fwd, 59-GTCTTGCACGGTGGAGGTAT-39; typing_rev, 59-CCCAGACGT CTCTCAGCTTC-39, and the T7 endonuclease I assay. Briefly, PCR product was boiled for 10 min at 98 uC and annealed by slowly cooling down to room temperature. The reaction was subsequently incubated with T7 endonuclease I (NEB) and analysed on a 2% agarose gel. Appearance of additional bands indicated mutations at the Mlkl locus. Additionally the PCR product was subjected to ApaLI restriction (NEB) with a lack of cleavage indicating the presence of a mutation. Mutations in the Mlkl locus were identified by sequencing the PCR product (GATC-Biotech). IEC isolation and immunoblotting. IECs were isolated by sequential incubation of intestinal tissue in 1 mM dithiothreitol (DTT) and 1.5 mM EDTA solutions as described previously 40 . Cell lysates from IECs and keratinocytes were prepared as described 41, 42 . Lysis buffer was supplemented with protease and phosphatase inhibitor tablets (Roche). Cell lysates were separated on SDS-PAGE and transferred to PVDF membranes (IPVH00010, Millipore). Membranes were probed with primary antibodies against the following proteins: RIPK1 (610459, BD Biosciences), RIPK3 (ADI-905-242-100), cIAP1 (ALX-803-335-C100, Enzo), IkBa (sc-371), TRAF2 (sc-876), TRAF3 (sc-949), TRADD (sc-7868), p65 (sc-372), c-Rel (sc-71), HDAC1 (sc-7872), b-actin, (sc-1616, Santacruz), phospho-p65 (3033), JNK (9252), RelB (4922), phospho-p38 (9211), p38 (8690), phospho-ERK (9101), ERK (9102, Cell Signaling), phospho-JNK (44-682G, Invitrogen), p100/52 (NR1495), p105/50 (NR1157, NCI BRB), a-tubulin (T6074, Sigma), TRAF6 (597, MBL), c-FLIP (AG-20B-0005-C100, Adipogen), followed by secondary HRP-coupled antibodies (GE Healthcare and Jackson ImmuneResearch) and developed with chemiluminescent detection substrate (GE Healthcare and Thermo Scientific). Isolation of lamina propria cells and flow cytometry. Colon and small intestine lamina propria cells were isolated using a modified version of a previously described protocol 43 . In brief, after removal of Peyer's patches, small intestine and colon tissues were incubated at 37 uC in HBSS containing 4% FCS, 10 mM HEPES and 5 mM EDTA. The remaining tissue was cut into small pieces and digested in HBSS containing 4% FCS, 10 mM HEPES, Dispase II (0.15 mg ml Histology. Intestinal tissues were fixed in 4% paraformaldehyde, skin samples in 10% formalin and embedded in paraffin and cut in 3-5 mm sections. Paraffin sections were rehydrated and heat-induced antigen retrieval was performed in citrate buffer, TRIS buffer or by proteinase K treatment. Primary antibodies for immunohistochemistry were anti-CD45 (550566, eBioscience), anti-Gr-1 (551459, BD Biosciences and MCATTIGA, Serotec), anti-F4/80 (clone A3-1, homemade), anti-B220 (clone RA3 6B2, homemade), anti-CD3 (ab5690, Abcam), anti-active caspase 3 (9661, Cell signalling and AF835, R&D Systems), anti-Ki67 (M724901, Dako), antihuman lysozyme (A0099, Dako). Biotinylated secondary antibodies were purchased from Perkin Elmer and Dako. Stainings were visualized with ABC Kit Vectastain Elite (Vector Laboratories) or Streptavidin-HRP (Millipore) and DAB substrate (DAKO and Vector Laboratories). Incubation times with DAB substrate were equal for all samples. Periodic acid-Schiff (PAS) reaction was performed according to standard protocols. Endogenous alkaline phosphatase activity was visualized using Vector Red Alkaline Phosphatase Substrate Kit according to the manufacturer's instructions (SK-5100, Vector Laboratories). Immunostainings on skin sections were performed as previously described 42 , Gr-1 staining was performed on cryo-sections. For assessment of intestinal pathology, H&E-stained intestinal sections were subjected blindly to a semiquantitative composite histological pathology scoring system as described previously 44 . Microscopic quantification of epidermal thickness was performed by measurement of epidermal thickness in four different back skin areas for each mouse. In each field, four measurements were performed. The percentage of the inflamed area was determined by measuring the cumulative number of the inflamed areas in relation to the total area of one section from back skin of each mouse. The number of CC3 1 and CC3 2 dying cells was determined on the same skin section by staining with anti-CC3 antibodies and counterstaining with H&E. Dying CC3 2 keratinocytes were identified by their pyknotic nuclei and eosinophilic cytoplasm. Near native imaging. Sections for imaging of mCherry at near native conditions were prepared as described 45 . Briefly, the intestine was dissected, thoroughly rinsed and fixed in 4% PFA for 20 min at room temperature. Tissue was embedded in 4% low melting agarose and sectioned with a vibrating blade microtome (Leica) at 150 mm. Permeabilization and staining were performed in PBS supplemented with 1% (wt/vol) BSA, 1% (vol/vol) dimethylsulphoxide (DMSO) and 2% (vol/vol) Triton X-100. Paneth cells were visualized with anti-lysozyme antibody and goat anti-rabbit IgG Alexa-488 (Molecular Probes, A11008). Images of fluorescent stainings were acquired with a Zeiss Meta 510 confocal laser-scanning microscope. Isolation and culture of primary murine keratinocytes. Isolation and culture of primary murine keratinocytes was performed as described previously 46 . Isolation and culture of intestinal organoids. Small intestinal crypts were isolated and grown to organoids as described previously 47 . Deletion of RIPK1 in organoid cultures from RIPK1 tamIEC-KO mice was induced by addition of 100 nM 4-OH-tamoxifen 
